Cognitive-motor Telerehabilitation in MS (CoMoTeMS)

May 4, 2026 updated by: Universitair Ziekenhuis Brussel

Cognitive-motor Telerehabilitation in Multiple Sclerosis

The primary goal of this project is providing evidence that a home-based combined cognitive-motor training program improves cognition in persons with multiple sclerosis (MS), compared to single cognitive and motor rehabilitation. Secondary goals are to assess the effects on walking performance and to identify the mechanisms of improvement and predictors of treatment response. The main backbone of this project will be a randomized controlled two-centre clinical trial, in which an at-home computerised cognitive-motor rehabilitation program using telemedicine aimed at improving working memory in persons with MS will be evaluated. Based on the information gathered during this trial, possible mechanisms of improvement will be identified by analysing anatomical and neurophysiological changes on structural MRI and resting-state and task-related EEG before and after rehabilitation. Furthermore, factors that can predict treatment response to the rehabilitation program will be identified.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Brussels, Belgium
        • Recruiting
        • Universitair Ziekenhuis Brussel
        • Contact:
          • Guy Nagels
      • Melsbroek, Belgium
        • Recruiting
        • National MS Center Melsbroek
        • Contact:
          • Miguel D'Haeseleer

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Clinically definite multiple sclerosis (revised McDonald criteria 2017)
  • Expanded Disability Status Scale (EDSS) below 6.0
  • Digit span backwards z-score between [-3 and -0.5] standard deviations below the median of the normative values
  • Age between 18 and 65
  • Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)

Exclusion Criteria:

  • Cognitive rehabilitation within six months before inclusion
  • Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial
  • Start of or switch in immunomodulator treatment within three months before inclusion
  • Less than one month post-exacerbation
  • Major psychiatric or medical disorder that could influence cognitive functions
  • Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test
  • Unable or unwilling to undergo EEG or MRI
  • Refusing informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Cognitive-motor training group
For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
Other Names:
  • BrainStim
For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
Active Comparator: Cognitive training group
For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used. This is a computer-aided program with more than 30 modules focusing on different domains of cognition. RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417). Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory. Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
Other Names:
  • BrainStim
Active Comparator: Motor training group
For the motor treatment intervention a patient-tailored aerobic training program will be used. Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session. The training will be carried out individually at home, without therapist supervision. All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer. Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Digit span backwards
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of working memory
0 weeks, 12 weeks, 24 weeks, 64 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of cognition in MS
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Corsi backwards
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of working memory
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Expanded Disability Status Scale (EDSS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of disability in MS
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in 6-Minute Walk Test (6MWT)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of walking performance
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in 25-Foot Walk Test (25FWT)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of walking performance
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in 9-Hole Peg Test (9HPT)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of upper extremity function
0 weeks, 12 weeks, 24 weeks, 64 weeks
MRI T1 3D BRAVO scan
Time Frame: 0 weeks, 12 weeks, 24 weeks
Cortical volume, volumes of white matter and deep grey matter
0 weeks, 12 weeks, 24 weeks
MRI T2 FLAIR 3D Cube scan
Time Frame: 0 weeks, 12 weeks, 24 weeks
Lesion volume
0 weeks, 12 weeks, 24 weeks
Synthetic MRI
Time Frame: 0 weeks, 12 weeks, 24 weeks
Contrast weighted images based on measurements of tissue properties from a single acquisition
0 weeks, 12 weeks, 24 weeks
resting-state EEG
Time Frame: 0 weeks, 12 weeks
functional connectivity using graph theoretical measures
0 weeks, 12 weeks
task-related EEG - auditory oddball paradigm
Time Frame: 0 weeks, 12 weeks
functional connectivity using graph theoretical measures, event-related potentials
0 weeks, 12 weeks
task-related EEG - adjusted SDMT paradigm
Time Frame: 0 weeks, 12 weeks
functional connectivity using graph theoretical measures, event-related potentials
0 weeks, 12 weeks
task-related EEG - n-back paradigm
Time Frame: 0 weeks, 12 weeks
functional connectivity using graph theoretical measures, event-related potentials
0 weeks, 12 weeks
Diffusion weighted image (DWI)
Time Frame: 0 weeks, 12 weeks, 24 weeks
structural connectivity using graph theoretical measures; diffusion tensor image parameters
0 weeks, 12 weeks, 24 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of anxiety and depression
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Fatigue Scale for Motor and Cognitive functions (FSMC)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of fatigue in MS
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Visual Analogue Scale (VAS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
VAS on the impact of perceived cognitive symptoms on daily life
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in 36-Item Short Form Survey (SF-36)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of quality of life Only Dutch-speaking participants
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Multiple Sclerosis Impact Scale-29 (MSIS-29)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of quality of life in MS Only Dutch-speaking participants
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Multiple Sclerosis-59 (SEP-59)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of quality of life, combination of SF-36 and MS-specific questions Only French-speaking participants Of note, the French title of this questionnaire is Sclérose En Plaques-59.
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Cognitive Leisure Activity Scale (CLAS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of baseline cognitive activities
0 weeks, 12 weeks, 24 weeks, 64 weeks
Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
Measure of baseline physical activities
0 weeks, 12 weeks, 24 weeks, 64 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Guy Nagels, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Estimated)

August 31, 2027

Study Completion (Estimated)

August 31, 2027

Study Registration Dates

First Submitted

April 14, 2022

First Submitted That Met QC Criteria

April 25, 2022

First Posted (Actual)

May 2, 2022

Study Record Updates

Last Update Posted (Actual)

May 8, 2026

Last Update Submitted That Met QC Criteria

May 4, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Multiple Sclerosis

Clinical Trials on Cognitive training

Subscribe